Denver-area Hospitals in 2025, Ranked by Patient Discharges
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
08-08-2025
- Business Journals
Denver-area Hospitals in 2025, Ranked by Patient Discharges
Information on The List was supplied by the Colorado Department of Public Health and Environment and the Colorado Department of Health Care Policy & Financing. The Denver-area is defined as the seven-county metro (Adams, Arapahoe, Boulder, Broomfield, Denver, Douglas and Jefferson counties).
Yahoo
06-08-2025
- Yahoo
Comvest Credit Partners Provides Financing to Allied OMS for Refinancing and Growth
Investment coincides with strategic growth investment led by 65 Equity Partners WEST PALM BEACH, Fla., August 06, 2025--(BUSINESS WIRE)--Comvest Credit Partners, a leading provider of flexible direct financing solutions to middle-market companies, is pleased to announce that it is acting as Administrative Agent on a $245 million senior secured credit facility (the "Financing") for Allied OMS ("Allied" or the "Company"), a Southlake, Texas-based management services organization (MSO) focused on oral and maxillofacial surgery practices. The Financing will be used to refinance Allied's existing debt and support its future growth initiatives. It coincides with a strategic growth investment in the Company led by 65 Equity Partners alongside co-investor Everberg Capital. Comvest Credit Partners also made a preferred equity investment in the Company. Allied is a doctor-led and doctor majority-owned specialty medical and dental service organization. Since its inception in 2020, the MSO has grown to support a network of 38 oral and maxillofacial surgery practices across more than a dozen states nationwide. The practices offer a wide range of generally critical, non-elective procedures, including tooth extractions, corrective jaw surgery, oral cancer treatments, and dental implants. "We are pleased to deliver a customized credit financing solution to support Allied's ongoing growth," said Tom Goila, Partner and Co-Head of Healthcare at Comvest Credit Partners. "We believe Allied is a well-diversified and steadily growing business led by a highly experienced management team of physicians and operating specialists with a clear focus on acute oral care. We look forward to deepening our relationship with both the Company and 65 Equity Partners." "Comvest Credit Partners brought significant institutional expertise in healthcare investing, including prior experience in the oral care sector, which was key to completing this transaction on an accelerated timeline. They also provided the financial capacity to support our goals for acquisitive and de novo growth as we expand our services, grow our practice network and scale our operations," said Dan Hosler, Allied's CEO and Founder. About Allied OMS Allied OMS is a doctor-owned, doctor-led, and doctor-governed MSO that partners with oral and maxillofacial surgery practices across the U.S. Combining the autonomy of private practice with the scale and sophistication of institutional support, Allied OMS empowers surgeons to lead the future of their specialty. The company currently supports surgeons in 50+ locations and maintains doctor leadership across all major committees and its Board of Directors. For more information, visit About 65 Equity Partners 65 Equity Partners is a global investment firm that partners with founders, families, and entrepreneurs across North America, Europe and Asia to build sustainable, long-term value. We invest in leading businesses across the healthcare, industrial, business services, technology, and consumer sectors. Backed by Temasek, as an independently managed investment platform with US$3.3 billion in funds under management, we provide equity and structured capital solutions to established companies with regional or global growth ambitions. With offices in Singapore, New York, San Francisco, London and Paris, we leverage our local roots, international network and the deep expertise of our broader ecosystem. For more information, visit About Comvest Credit Partners Comvest Credit Partners, the direct lending platform of Comvest Partners, focuses on providing flexible financing solutions to middle-market companies. Comvest Credit Partners provides senior secured, unitranche, and second lien capital to sponsored and non-sponsored companies in support of growth, acquisitions, buyouts, refinancings, and recapitalizations, with credit facilities up to $300 million-plus. For more information, please visit About Comvest Partners Comvest Partners ("Comvest") is a private investment firm that has provided equity and debt capital to well-positioned middle-market companies throughout North America since 2000. Through its private equity, direct lending and opportunistic credit investment platforms, Comvest offers tailored investment solutions across the capital structure along with deep industry expertise, operating resources, a collaborative approach, and significant transaction experience as an active investor. In 2025, Comvest Partners proudly celebrates 25 years of investment management leadership, and today manages $16.6 billion in assets, with over $19.2 billion invested since inception. Comvest Partners is based in West Palm Beach, with offices in Chicago and New York City. For more information, please visit View source version on Contacts For more information, please contact: Tom Goila, Partner, Co-Head of Healthcare, Comvest Credit Partners – Bryce Peterson, Managing Director, Co-Head of Healthcare, Comvest Credit Partners – Kevin Blitz, Managing Director, Comvest Credit Partners – Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-08-2025
- Yahoo
METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing's Biopharmaceutical Innovation Engine
BEIJING, China, Aug. 4, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB 400 million Series D financing round. The announcement was made at the Zhongguancun (Daxing) Cell and Gene Therapy Industrial Park, a key hub for Beijing's life sciences sector. Financing Co-led by Beijing Medical and Health Industry Investment Fund and Daxing Industrial Investment Fund The Series D round was co-led by the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund. The new capital will be used to accelerate METiS' core strategic initiatives, including automation upgrades to its proprietary platform, in-house pipeline development, expansion of global partnerships, and recruitment of world-class talent. Left: Dr. Chris LAI, Co-founder and CEO of METiS Technologies; Right: Mr. REN Peng, Chairman and General Manager, Shunxi Management Co., Ltd., a General Partner of the Beijing Medical and Health Industry Investment Fund The Beijing Medical and Health Industry Investment Fund (Limited Partnership) is one of eight major industrial funds established with support from the Beijing Municipal Government. It focuses on innovative pharmaceuticals, advanced medical devices, and emerging technologies such as cell and gene therapy (CGT) and digital health. The fund plays a key role in accelerating the city's biotech innovation ecosystem. Mr. REN Peng, Chairman and General Manager of Shunxi Management Co.,Ltd. commented: "Healthcare is a cornerstone of Beijing's innovation-driven strategy and a vital engine of emerging productivity. With the launch of the city's AI+Healthcare Innovation Action Plan, Beijing is strategically integrating AI with life sciences to lead the next phase of high-quality growth. Our RMB 20 billion fund reflects our commitment to advancing innovation in CGT. METiS fills a critical gap in advanced formulation and delivery systems, and we believe their technology will set new standards in AI-powered nanodelivery." Mr. LI Ming, Chairman of Beijing Daxing District Investment Group Co., Ltd., added: "Daxing District is committed to making biopharma a core pillar of its economic growth strategy. The launch of the OpenCGT platform marks a major milestone that will accelerate the commercialization of cutting-edge technologies, while attracting top global talent, capital, and innovation to Daxing - enhancing our competitiveness in CGT on the world stage." Mr. HUANG Hantao, Deputy General Manager of CICC Capital, noted: "We are grateful for the strong support from Beijing's leadership, Shunxi Management, and Daxing District across policy, capital, talent, and infrastructure. METiS has made tremendous progress over the past two years. As a long-term investor, CICC Capital will continue to support the company in R&D collaborations with our portfolio companies, clinical development, talent acquisition, and capital markets—empowering the next wave of breakthroughs in AI-enabled drug delivery."
